News | Intra-Aortic Balloon Pumps (IABP) | March 11, 2016

Teleflex Announces Worldwide Recall of Arrow IAB Catheter and Percutaneous Insertion Kits

Company has received 13 reports of adverse events, including six serious injuries and one death

Teleflex, Arrow IAB catheter, intra-aortic balloon pump, worldwide recall

March 11, 2016 — Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous insertion kits. The Arrow IAB is inserted in the aorta and provides mechanical circulatory support for cardiac patients, by inflating and deflating at different phases of the cardiac cycle to increase cardiac output and decrease the work of the heart.

The U.S. Food and Drug Administration (FDA) has classified the recall as a Class I recall. FDA defines a Class I recall as, “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

On Feb. 9, Teleflex initiated a worldwide recall of 47,140 units distributed to hospitals, clinics and medical centers throughout the United States and globally. The systems are being recalled because the sheath body may become separated from the sheath hub. If the separation occurs, the patient may bleed from the sheath. If bleeding is not promptly addressed, significant blood loss or exsanguination may occur. Interruption or loss of intra-aortic balloon pump treatment may also occur. At the time of the recall, there were 13 adverse events reported, including six serious injuries and one death.

Teleflex notified domestic distributors and customers via an Urgent Medical Device recall letter dated Feb. 11, 2016. Consumers who have affected product should immediately discontinue use and return all affected product to Teleflex.

Teleflex has notified the FDA of this action. The full list of affected lot numbers can be found here

For more information: www.teleflex.com


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now